

# 5- Fluorouracil leucovorin

\*, †, ‡  
\*‡, \*‡, \*‡, \*‡, \*‡  
\*‡, \*‡, ‡, †, ‡, ‡, \*‡

=Abstract=

## Effect of 5- FU plus leucovorin for adjuvant chemotherapy according to dose related factors in colon cancer

Kwang Yong Shim, M.D.\*‡ Joong Bae Ahn, M.D.\*‡ Hei Chul Jung, M.D.\*‡  
Joon Oh Park, M.D.\*‡ Nae Choon Yoo, M.D.\*‡ Sun Young, Rha, M.D.\*‡  
Jae Kyung Roh, M.D.\*‡ Byung Soo Kim, M.D. ‡ Nam Kyu Kim, M.D. ‡  
Jin Sik Min, M.D. ‡, ‡ and Hyun Cheol Chung, M.D.

*Department of Internal Medicine\*, General Surgery ‡,  
Yonsei University College of Medicine, Yonsei Cancer Center ‡*

**Background :** In patients with stage C colon cancer, surgery followed by adjuvant chemotherapy with 5-fluorouracil (5-FU)/leucovorin (LV) is considered to be the standard treatment. However, the objects of adjuvant therapy and the duration of treatment are still matters of controversy. We investigated the effect of dose related factor(delivered total dose of 5-FU per body square meter, actual dose intensity and relative dose intensity) of the adjuvant 5-FU/leucovorin regimen on survival in colon cancer.

**Methods :** Of the colon cancer patients with Duke's B2 and C stage diseases treated with curative resection from December, 1990 to December, 1996, 139 patients treated with 5-FU/LV as an adjuvant chemotherapy were evaluated. The delivered total dose of 5-FU per body square meter, actual dose intensity and relative dose intensity were obtained. The patients were divided into two groups according to the median value of each factor and the survival rates were compared.

**Results :** The total dose of 5-FU administrated per body square meter had a significant effect on the 5-year disease free and overall survival in stage B2 and C colon cancer patients(B2;  $p=0.025$ ,  $p=0.045$ , respectively, C;  $p=0.011$ ,  $p=0.0002$ , respectively). But survival was not affected by the dose intensity. Multivariate analysis demonstrated that only the total dose of 5-FU administrated per body surface area affected the 5-year disease free and overall survival( $p=0.0016$ ,  $p=0.0007$ , respectively).

**Conclusion :** It can be concluded that the total dose of 5-FU administered is more important than the DI in adjuvant chemotherapy of colon cancer and the total dose of 5-FU had a significant

---

• : 1999 12 9  
• : 2000 3 25  
• : , 134, (120- 752)  
E- mail : rha7655@yumc.yonsei.ac.kr  
(1998)

- Kwang Yong Shim, et al : Effect of 5-FU plus leucovorin for adjuvant chemotherapy according to dose related factors in colon cancer -

effect on the survival rate in colon cancer patients. To confirm the total dose effect of 5-FU on survival in this study, multi-institutional, prospective randomized studies should be carried out.(Korean J Med 59:290-299, 2000)

**Key Words** : Colonic neoplasms; Chemotherapy, Adjuvant; Fluorouracil; Dosage forms

5-FU leucovorin 1, 2 8, 20-40% 9, 10.

가, 5-FU/ leucovorin

가 NSABP C-03 MOF

1), Intergroup 0089

, 30% , 6 5-FU/leucovorin 12

2. 5-FU/levamisole 가

12) 5FU/levamisole 5-FU/ leucovorin

가 leucovorin

5-Fluorouracil( 5-FU ) 1958

. 1960 5-FU Duke B2, C2

5-FU leucovorin

15-20% 3. 1970 (1) 5-FU total dose

5-FU methyl-CCNU, vincristine (2) 5-FU dose intensity

5-FU

4. 1988 National Surgical Adjuvant Breast and Bowel Project(NSABP) Duke B C

5-FU, semustine 1.

vincristine(MOF) 1990 1 1996 12

5. North Central Cancer Treatment Group(NCCTG) Intergroup 가 Duke B2, C

5-FU levamisole , 5-FU/leucovorin

가

40% 6. Duke C

가 1990 가 ECOG 0-2 , , ,

5-FU, levamisole Duke C 가 139 .

7.

1980 5-FU 가 2.

leucovorin 5-FU fluoro- 3-4

deoxyuridine monophosphate(FdUMP) . 5-FU 400 mg/m<sup>2</sup> leucovorin 20

mg/m<sup>2</sup> 1 5 . log-rank test ,  
 4 1 . CBC  
 , 가 3,000/ Cox-regression test . 5-FU  
 mm<sup>3</sup> , 가 100,000/mm<sup>3</sup>  
 1 Chi-square test t-test  
 가 3,000/mm<sup>3</sup> , 가 100,000/mm<sup>3</sup> , Chi-square test  
 5-FU 25% .  
 . WHO grade III  
 , 5-FU 25%  
 . B2 6 , C 1.  
 12 .  
 3. 24- 76 가 55 ,  
 87 (63%), 52 (37%) ,  
 ECOG 0- 1 118 (85%)  
 . Duke B2가 81  
 , X , , (58%), C가 58 (42%) ,  
 5 6 CEA, 61 (44%), S 52 (37%) .  
 CEA 5 ng/mL 가 93 (73%)  
 , 5ng/mL 가 34 (27%) .  
 . 27 101 well differentiated가 27 , moderately  
 50 differentiated가 85 , poorly differentiated가 13  
 . B2 6 , C  
 4. 가 12 .  
 5-FU (total Table 1 .  
 dose) 5-FU  
 ( ; mg/m<sup>2</sup>) , 2. 5-FU ,  
 (actual dose intensity)  
 5-FU가 가 5-FU B2  
 5-FU 가 12.9 g/m<sup>2</sup> ; 3.5- 27.4 g/m<sup>2</sup>  
 ( ; ) ( ; mg/m<sup>2</sup>/week) C 20.6 g/m<sup>2</sup> ; 1.9- 30.7  
 . (relative dose intensity) g/m<sup>2</sup> . B2  
 가 462 mg/m<sup>2</sup>/week( ; 353- 598 mg/m<sup>2</sup>/week)  
 C 498 mg/m<sup>2</sup>/week( ;  
 293- 678 mg/m<sup>2</sup>/week) . B2  
 92.4( ; 70.5- 119.5) C  
 93.5( ; 58.5- 135.5) .  
 (1999 3 )  
 3.  
 B2 5 86.2% C  
 5 68.9% (Figure 1A). B2  
 Kaplan- Meier method 5 87.1% C 5

**Table 1. Patients characteristics**

	Delivered 5-FU*		<i>p</i> - value	Total
	Below the median	Above the median		
Number of patients	70	69		139
Male:Female	1.3:1 (40:30)	2.1:1 (47:22)	0.181	1.7:1 (87:52)
Age				
Median(year)	56	51	0.259	55
Range	24- 73	30- 76		24- 76
ECOG status				
0	5	5	0.265	10
1	51	57		108
2	14	7		21
Primary lesion				
Rt	29	32	0.484	61
Transverse	4	8		12
Lt	8	6		14
Sigmoid	29	23		52
Differentiation				
Well	11	16	0.732	27
Moderately	45	40		85
Poor	7	6		13
Mucinous	7	7		14
Preop. CEA (ng/mL)				
< 5	44	49	0.251	93
5	20	14		34
Cycle in B2 stage				
Median	6	12	0.0001 †	6
Range	2- 7	6- 13		2- 13
Cycle in C stage				
Median	7	12	0.0001 †	12
Range	1- 13	9- 14		1- 14
Duke's stage				
B2	41	40	0.943	81
C	29	29		58

\* ; means the delivered total dose of 5-FU per body square meter

† ; significant difference

75.7% (Figure 1B). 5-FU 80% (p=0.446). 5 85%,

, B2 4.

C 5 7† (p=0.045, p=0.0002) (Figure 2A, B). 139 25 18.0%

5 85%, (11.1%) 7†, C 16 (27.6%) 7† 9

80% (p=0.446). 5 (20%), 5 (20%), 13 (52%),

**Figure 1.** Survival in total patients according to Duke's stage. (A) DFS (B) OS.

**Figure 2.** Overall survival according to the total dose of 5-FU per body square meter (A) Duke's B2 stage (B) Duke's C stage.

	2 (8%)	.	C	10	
	11 , 3	.			( $p=0.275$ ).
Table 2	.	B2	5	5.	
	11	4 가	36%	1,184	grade 3
	, 6	70	5 7%	11 (0.9%)	, grade
6				3	.
( $p=0.004$ ).	C	9		grade 3	, 가
	22	11 (50%)가	10	14 (1.2%),	56 (4.7%), 9 (0.8%)가
	36	5 (14%)가	10	.	
( $p=0.003$ ).					
,	B2	6			가
			( $p=0.012$ ),	Duke	A

- Kwang Yong Shim, et al : Effect of 5-FU plus leucovorin for adjuvant chemotherapy according to dose related factors in colon cancer -

5 90% , B 70% 12  
C 5-FU/levamisole 6 5-FU/  
50% , B C leucovorin .  
가 NCCTG 5-FU/levamisole, 5-FU/levamisole/leu-  
covorin 가 6 , 12 4  
가 B. 1980 NSABP , 5-FU/levamisole/leucovorin  
C-01 5-FU methyl-CCNU, vincristine 6 가  
(MOF) 4 가 12  
가 Moertel 18.  
Duke C 5-FU  
levamisole 1 40%, 5-FU  
33% 9 1990  
NIH Consensus Development Conference Duke C , B2  
5-FU levamisole 1 5 95%, 95%  
7. 78%, 80%  
( $p=0.025$ ,  $p=0.045$ ), C  
가 5  
가 90%, 97%  
5-FU 52%, 55%  
( $p=0.011$ ,  $p=0.0002$ )(Figure 2A, B).  
N- (phosphonacetyl)- L- aspartic  
acid(PALA)14, interferon15, leucovorin16  
, 5-FU leucovorin 5-FU  
5-FU/leucovorin , B2  
가 1987 5 94%, 97%  
NSABP C-03 leucovorin 80%, 82%  
500 mg 5-FU ( $p=0.036$ ,  $p=0.028$ ), C  
(5-FU 500 mg/m2 leucovorin 500 mg/m2 every 5  
week for 48 weeks). NSABP C-01 67%, 87% ,  
가 MOF (p=0.169),  
, 5-FU/leucovorin MOF 5 77%,  
30% 3 96%  
가 11. NCCTG (p=0.045).  
20 mg leucovorin C 가 B2  
5-FU/leucovorin  
(5-FU 425 mg/m2 x 5 days IVB. leucovorin 20 mg/m2  
x 5 days IVB every 4 weeks, 6 cycles).  
6 가 .  
5 5 IMPACT B2  
40%, 33% 17. 5-FU/ leucovorin

- : 59 3 481 2000 -

5 5 85% 80%

73% 76% , 5 80%

82% B2 가 5-FU

가 60%

19, NSABP 가

C-01 C-04 5-FU 가 61%

B2 C 가

. 5-FU

20, B2가 5

5-FU 가 97%,

B2 93% ( $p=0.542$ ), 5-FU

C 5-FU 가

5 96% 5 71%, 69%

5 60-70% ( $p=0.987$ ).

가 5-FU

B2 B2 5

5-FU 36% 6

7% 6 ( $p=0.004$ ). C 10

가 9

가 ( $p=0.003$ ).

**Table 2. Stepwise recurrence according to cycles**

No. of cycles	B2		C	
	No. of patients	No. of recur ( )*	No. of patients	No. of recur ( )*
1	-	-	1	0
2	1	0	3	2(1)
3	2	2(1)	3	2(1)
4	5	1	1	0
5	3	1	2	2(1)
6	35	2	4	1
7	3	2	1	0
8	4	1(1)	2	1(1)
9	2	0	5	3(3)
10	-	-	3	0
11	1	0	1	0
12	22	0	29	5
13	3	0	2	0
14	-	-	1	0
Total	81	9(2)	58	16(7)

( )\* ; means the number of recurrence during the adjuvant chemotherapy

**Table 3. Univariate and multivariate analysis of dose related factors influencing disease-free survival and overall survival**

factors	5- year DFS	p- value*	p- value †	5- year OS	p- value ‡	p- value §
5-FU dose		0.0018	0.0016		0.0011	0.0007
above the median	94			96		
below the median	71			79		
Actual DI		0.7576			0.4604	
above the median	81			90		
below the median	86			86		
Relative DI		0.7576			0.4604	
above the median	81			90		
below the median	86			86		
No. of cycles		0.0509			0.1673	
above the median	94			94		
below the median	79			86		

\* ; univariate analysis of 5-year DFS within each factor, † ; multivariate analysis of 5-year DFS, among the factors, ‡ ; univariate analysis of 5-year OS within each factor, § ; multivariate analysis of 5-year OS among the factors, ; means the delivered total dose of 5-FU per body square meter

, B2 6  
( $p=0.012$ ),  
C 10 : Duke C  
( $p=0.275$ ), 5-FU/levamisole 5-FU/LV  
가 가  
(Table 2).  
5-FU , 가  
5 Duke B2, C  
5-FU leucovorin  
5-FU (1) 5-FU total  
dose (2) 5-FU dose intensity  
. 139 45  
, : 1990 1 1996 12  
가 Duke B2,  
C 5-FU/LV  
139 5-FU/LV  
5-FU 가 3-4  
5-FU 5-FU 400 mg/m<sup>2</sup> leucovorin 20 mg/m<sup>2</sup> 1  
5 4 1  
: B2 5 86.2%  
C 5 68.9% B2 5  
가 87.1% C 5



75.7% . 5- FU  
 , B2 C 5  
 가 (B2;  $p=0.025$ ,  
 $p=0.045$ , C;  $p=0.011$ ,  $p=0.0002$ ).

5- FU ,  
 )  
 5- FU  
 : 5- FU  
 가

## REFERENCES

- 1) . 5  
 38:157- 164, 1995
- 2) Vaughn DJ, Haller DG. *The role of adjuvant chemotherapy in the treatment of colorectal cancer. Hematol/Oncol Clinics of North America* 11:699- 719, 1997
- 3) Higgins GA. *Current status of adjuvant therapy in the treatment of large bowel tumor. Surg Clin North Am* 63:137- 150, 1983
- 4) Moertel CG. *Chemotherapy of Gastrointestinal Cancer. N Engl J Med* 299:1049- 1052, 1978
- 5) Wormald N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W. *Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst* 80:30- 36, 1988
- 6) Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. *Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma. N Engl J Med* 322:352- 358, 1990
- 7) NIH Consensus Conference. *Adjuvant Therapy for Patients With Colon and Rectal Cancer. J Am Med Assoc*, 264:1444- 1450, 1990
- 8) Keyomarsi K, Moran RG. *Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemia cells. Cancer Res* 46:5229- 5235, 1986
- 9) Madajewicz S, Petrelli N, Rustum YM, Campbell J, Herrera L, Mittelman A, Perry A, Creaven PJ. *Phase I-II trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res* 44:4667- 4669, 1984
- 10) Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marguet J, Vandenbulcke JM, Misset JL, Schwarzenbergh L, Fourtillan JB, Gaget H, Mathe G. *Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high dose folinic acid. J Clin Oncol* 4:685- 696, 1986
- 11) Wolmark N, Rockette H, Fisher B, Wickerham L, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, DeFusco A, Joshimsen P. *The Benefit of Leucovorin-Modulated Fluorouracil as Postoperative Adjuvant Therapy for Primary Colon Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol* 11:1879- 1887, 1993
- 12) Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. *Fluorouracil (FU), Leucovorin (LV) and Levamisole (LEV) Adjuvant Therapy for Colon Cancer: Preliminary Results of INT-0089. Proc Am Soc Clin Oncol* 15:211, 1996
- 13) Cohen AM, Minsky BD, Schilsky RL. *Cancer. principles and practices of oncology. 5th ed. p. 1144- 1196, Philadelphia, Lippincott, 1997*
- 14) Buroker TR, Moertel CG, Fleming TR. *A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol* 3:1624- 1631, 1985
- 15) York M, Greco FA, Figlin RA. *A randomized phase III trial comparing 5-FU with or without interferon alpha-2a for advanced colorectal cancer. Proc Am Soc Clin Oncol* 12:200, 1993
- 16) Poon MA, O'Connell MJ, Wieand HS. *Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol* 9: 1967- 1972, 1991
- 17) O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS. *Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol* 15:246- 250, 1997

- 18) O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A. *Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol* 16:295-300, 1998
- 19) Anonymous. *Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol* 17:1356-1363, 1999
- 20) Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H. *Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol* 17: 1349-1355, 1999